Trastuzumab is a monoclonal antibody that is one of the best options to treat breast cancer and stomach cancer. Trastuzumab injection is especially used for the treatment of certain HER-2 positive cancers or metastatic (cancer that has spread) breast cancer. It helps prevent the growth of certain tumors that produce additional amounts of the HER2 protein. It should be used only in patients whose tumors have shown additional amounts of this protein (HER2 overexpression). Trastuzumab can be used alone or with other cancer medicines (e.g., cyclophosphamide, carboplatin, doxorubicin, carboplatin, paclitaxel). Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Furthermore, other severe side effects include allergic reactions, lung disease, and heart failure. Trastuzumab may harm the baby during pregnancy. It works by binding to the HER2 binding and slowing down the duplication of the cells.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the trastuzumab injection market.
Top Impacting Factors
- Rise in prevalence of breast and gastric cancer contributes to the growth of the market.
- In addition, there are certain factors that are linked with high prevalence of the cancer and it includes the obesity, late pregnancy, and early age menstruation are some factors which boost the market growth.
- Change in lifestyle together with augmented consumption of alcohol and relentless smoking of cigarettes are likely to fuel the growth of the market.
- On the contrary, rise in awareness about the prevention and treatment of breast cancer and increase in investments in R&D activities to develop novel treatment for breast cancer are expected to offer lucrative growth opportunities for the expansion of the market during the forecast period.
- However, the side effects of trastuzumab such as nausea, fever, heart problems, infection, and others are expected to hamper the growth of the market.
Market Trends
New Product Launches to Flourish the Market
In December 2019, Biocon and Mylan launched Ogivri (trastuzumab-dkst), Trastuzumab Biosimilar in the USA. Mylan plans to offer Ogivri in 150 mg and 420mg strengths, increase access for the treatment of HER2-positive breast and gastric cancer.
In February 2020, Pfizer launched trastuzumab biosimilar to herceptin, Trazimera. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer.
In April 2020, Merck announced the launch of a biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). It is used for the treatment of breast cancer.
Key Benefits of the Report
- This study presents the analytical depiction of the trastuzumab injection market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Trastuzumab Injection Market Report
- Which are the leading market players active in the trastuzumab injection market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is trastuzumab injection market?
- What is trastuzumab injection market prediction in the future?
- Who are the leading global players in the trastuzumab injection market?
- What are the current trends and predicted trends?
- What are the key benefits of the trastuzumab injection market report?
Trastuzumab Injection Market Report Highlights
| Aspects | Details |
 By Indication |
|
 By End User |
|
 By Region |
|
 Key Market Players | Samsung Bioepis, Intas Pharmaceuticals, F.Hoffmann La Roche AG, Accord Healthcare Ltd, Merck, Amgen Inc, Celltrion Healthcare, Mylan, Pfizer Inc., Biocon Limited |
Loading Table Of Content...
